Femasys expands FemBloc trial enrollment

Femasys announced that it has activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, New York. The FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The FDA approved multi-center pivotal trial is designed to address the high unmet need that exists for women seeking permanent birth control for whom elective surgery remains the only option. “After just announcing the start of the FINALE trial in August, we are delighted to announce the first academic site is activated to enroll in FemBloc’s FINALE pivotal trial, led by a thought leader in the field of gynecology,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “We appreciate the long-standing support for the FemBloc technology evidenced by the prominent investigators who are electing to participate in the FINALE trial, as we work to bring this much needed option to women.”